

Department of Planning and Budget 2017 Fiscal Impact Statement

1. Bill Number: SB 1403

House of Origin	<input checked="" type="checkbox"/> Introduced	<input type="checkbox"/> Substitute	<input type="checkbox"/> Engrossed
Second House	<input type="checkbox"/> In Committee	<input type="checkbox"/> Substitute	<input type="checkbox"/> Enrolled

2. Patron: Dunnavant

3. Committee: Education and Health

4. Title: Board of Pharmacy to deschedule or reschedule cannabidiol upon publication of an interim final rule.

5. Summary: Directs the Board of Pharmacy to initiate action to deschedule or reschedule cannabidiol or any product containing cannabidiol that has been approved as a prescription medication by the U.S. Food and Drug Administration pursuant to 21 U.S.C. § 360bb and 21 U.S.C. § 355 within 90 days of publication in the Federal Register of an interim final rule.

7. No Fiscal Impact.

8. Fiscal Implications: This bill would not have a fiscal impact on the Commonwealth. Any costs to the Board of Pharmacy to initiate action to reschedule cannabidiol are minimal and can be absorbed by the agency.

9. Specific Agency or Political Subdivisions Affected: None.

10. Technical Amendment Necessary: No.

11. Other Comments: HB 1799, introduced by Delegate O'Bannon, is a companion bill.